p .01); this effect was independent of foreign travel" (p. 1150). They conclude, "Persons with ciprofloxacin-resistant Campylobacter infection have a longer duration of diarrhea than do persons with ciprofloxacin-susceptible Campylobacter infection. Additional efforts are needed to preserve the efficacy of fluoroquinolones" (p. 1150).
We have a number of concerns with these analyses. The following comments address some of them. Reexamining the raw data raises questions about the validity and general applicability of the stated conclusions and interpretations. Table 1 shows the mean number of illness-days (and no. of cases) of Campylobacter infection that (1) are acquired via foreign travel versus domestically and (2) are ciprofloxacin resistant versus ciprofloxacin susceptible. This table shows the unadjusted data, without adjustment for the additional subset-selection and statistical-modeling steps used by Nelson et al. Although foreign travel is strongly associated with resistance to ciprofloxacin, and also with longer mean duration of diarrhea, resistance to ciprofloxacin is clearly not associated with longer mean duration of diarrhea among cases of domestically acquired campylobacteriosis.
Any analysis that begins with crude data showing no apparent effect but that ends by concluding that there is a significant effect for some subsets of subjects must be especially diligent in the reporting of model diagnostics, as well as in correcting for potential model-selection bias, variableselection and -coding biases, data subsetselection bias, and multiple-testing biases, all of which can threaten study validity by producing an excessive number of false-positives [2, 3] . Nelson et al. do not report such recommended diagnostics and corrections, which leaves open the possibility that the reported effects and conclusions result from modeling errors and biases. To remove this possibility, it would be desirable to (1) use nonparametric models (e.g., analysis of classification trees [4] instead of analysis of variance), (2) report the results of modelvalidation tests, and (3) correct the reported significance levels, to account for biases associated with the use of multiple tests [3] . The potential practical importance of such corrections is suggested by the fact that our own classification tree-based analysis of the complete data set did not reveal any significant positive association between Campylobacter's resistance to ciprofloxacin and the duration of diarrhea.
The policy implications of Nelson et al.'s article also deserve reexamination. Their stated premise that "human infections with ciprofloxacin-resistant Campylobacter have become increasingly common" appears to be incorrect, insofar as ciprofloxacin-resistant Campylobacter infections in humans are less common than they used to be [5] . In an article published during 2004, Kassenborg et al. estimated that 326,000 fluoroquinolone-resistant Campylobacter infections occurred in humans during 1998 [6] . On the basis of both 2002 data from the National Antimicrobial Resistance Monitoring System and updated data from FoodNet, it can be estimated that there are now 280,000 fluoroquinolone-resistant Campylobacter infections in humans per year [7, 8] ; this represents a 14% reduction. The "human health consequences of such infections" (p. 1150) described in Nelson et al.'s article-that is, more days of diarrheaappear to be associated specifically with foreign travel: it is not clear that they are in fact "consequences" of resistance in cases of domestically acquired Campylobacter infection. The conclusion that "persons with ciprofloxacin-resistant infection had a longer mean duration of diarrhea than did the persons with ciprofloxacin-susceptible infection (P p .01)" does not appear to hold for cases of domestically acquired Campylobacter infection overall (see 
Reply to Cox et al.
To the Editor-Repeating comments they had made previously [1, 2] , Cox et al. [3] have provided a critique of our analysis of the FoodNet Campylobacter case-control study. Data from the FoodNet study, the largest reported case-comparison study of clinical outcomes of Campylobacter infections, demonstrated that resistance to fluoroquinolone (e.g., ciprofloxacin) is common in Campylobacter infections in humans and that persons with ciprofloxacin-resistant Campylobacter infection have a longer duration of diarrhea than do persons with ciprofloxacin-susceptibleCampylobacter infection. Using standard epidemiologic principles, we found a consistent, strong, and robust association between having a longer mean duration of diarrhea and ciprofloxacin-resistant Campylobacter infection [4] .
When Cox et al. examined the FoodNet data, which were obtained under the Freedom of Information Act, they concluded that foreign travel confounded the association between resistance to ciprofloxacin and duration of diarrhea. Their analysis, which did not consider the effect of taking antidiarrheal medication, concluded that resistance to ciprofloxacin was not associated with an increased duration of diarrhea. In the analysis conducted by the Centers for Disease Control and Prevention, state health departments, the US Department of Agriculture, and the US Food and Drug Administration (FDA), we included foreign travel as a variable in the analysis and found that, when antidiarrheal medication is included in the model, the inclusion of foreign travel does not change the observed consistent association between resistance to ciprofloxacin and duration of diarrhea; foreign travel is not consistently or strongly associated with a longer duration of diarrhea, nor does it confound the observation that resistance to ciprofloxacin is associated with a longer duration of illness. As we noted in our article [4] , taking antidiarrheal medication is associated with duration of diarrhea; failure to include the effect of antidiarrheal treatment leaves a major associated factor uncontrolled, producing spurious results.
We do not agree with the supposition by Cox et al. that ciprofloxacin-resistant Campylobacter infections are less common now than they were during 1998. The incidence of laboratory-confirmed Campylobacter infection has declined in the United States in recent years, as indicated by FoodNet surveillance data [5] , but the prevalence of Campylobacter resistance to ciprofloxacin has increased [6, 7] . When both the decline in the incidence of laboratory-confirmed Campylobacter infection and the increase in the prevalence of Campylobacter resistance to ciprofloxacin are taken into account, the incidence of ciprofloxacin-resistant Campylobacter
